ACZ885 also being investigated for rheumatoid arthritis using innovative personalized approach to treatment
BASEL, Switzerland | April 8, 2008 | New data demonstrate that ACZ885, a human monoclonal antibody in Phase III development, achieves long-lasting clinical remission in patients with genetic autoinflammatory diseases[1,2].
The results indicate that ACZ885 could develop into a major therapeutic advance in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare but serious life-long diseases including Muckle Wells Syndrome[3].
In the Phase II study, CAPS patients treated with ACZ885 showed an improvement in symptoms within one day and all achieved complete clinical remission within seven days[1]. Clinical remission lasted 115 days on average[1]. The results were presented today at the Fifth International Congress on Familial Mediterranean Fevers and Systemic Autoinflammatory Diseases in Rome.
"The latest findings are a promising step forward for patients with rare autoinflammatory diseases," said Trevor Mundel, MD, Head of Global Development Functions at Novartis Pharma AG. "We are optimistic that ACZ885 could become an innovative treatment option for patients affected by inflammatory diseases involving IL-1ß. ACZ885 reflects our commitment to developing innovative treatments that address unmet medical needs, in patients with serious but rare conditions."
ACZ885 is also being investigated in more common inflammatory diseases such as rheumatoid arthritis (RA), which affects up to 1% of the world’s population[4]. A study in RA currently under way uses an innovative tailored approach with biomarkers to predict response to treatment. If successful, this will give suitable patients a personalized approach to treating their disease.
Unlike other agents, ACZ885 blocks solely interleukin 1ß (IL-1ß), one form of interleukin-1 protein that causes the body to ‘attack’ itself in autoinflammatory diseases such as CAPS. Patients affected by CAPS have symptoms such as fever, fatigue, skin rash, painful joints and muscles, and severe headache. They can also suffer from more severe complications like hearing loss and amyloidosis, a group of diseases in which some organs accumulate high deposits of proteins causing kidney failure and leading to dialysis or transplantation[3].
The study results presented in Rome involved 20 patients with CAPS aged between six and 50 years, who received an injection of ACZ885 every two months dosed at 150 mg for adults or two mg per kilo body-weight for children[1,2]. ACZ885 was well-tolerated in the study, with only mild skin reactions at the injection site. The most common adverse events were upper respiratory tract infections[2].
"Traditional drugs for autoinflammatory diseases, which work by suppressing the immune system as a whole, are not always effective, while newer therapies control the disease better but are short-acting," said Professor Philip Hawkins of the National Amyloidosis Centre at the Royal Free and University College Medical School, London. "The data for ACZ885 are exciting for the medical community as symptoms disappeared within a few days of treatment and the response was sustained, so patients may only need to be treated every second month."
The potential of ACZ885 is reflected in its broad development program. In addition to the Phase III study program in CAPS and the Phase II study in rheumatoid arthritis, a Phase II study is also ongoing in another condition called Systemic Onset Juvenile Idiopathic Arthritis (SJIA).
Orphan drug status has already been granted to ACZ885 in the European Union and US for treating CAPS, and in the EU for SJIA. Orphan drugs are those designed to treat serious or life-threatening diseases affecting less than 200,000 people (in the US)5 or less than five out of 10,000 people (in the EU)[6].
About Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group’s continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
References
[1.] Lachmann H.J. et al. Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-beta monoclonal antibody (ACZ885): results from a subcutaneous administration study, oral presentation at FMFSAID, April 8 2008, Rome, Italy.
[2.] Kuemmerle-Deschner J.B. et al, Long lasting response to ACZ885 in patients with Muckle-Wells Syndrome, oral presentation at FMFSAID, April 8 2008, Rome, Italy.
[3.] http://www.capscommunity.com/index.html, Last access March 17, http://www.orpha.net/consor/cgi-bin/index.php, Last access March 17
[4.] Data Monitor Report, 2007.
[5.] http://www.fda.gov/orphan, Last access March 17, 2008
[6.] http://ec.europa.eu/health/ph_threats/non_com/rare_6_en.htm, Last access March 17, 2008
SOURCE: NOVARTIS
Post Views: 106
ACZ885 also being investigated for rheumatoid arthritis using innovative personalized approach to treatment
BASEL, Switzerland | April 8, 2008 | New data demonstrate that ACZ885, a human monoclonal antibody in Phase III development, achieves long-lasting clinical remission in patients with genetic autoinflammatory diseases[1,2].
The results indicate that ACZ885 could develop into a major therapeutic advance in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare but serious life-long diseases including Muckle Wells Syndrome[3].
In the Phase II study, CAPS patients treated with ACZ885 showed an improvement in symptoms within one day and all achieved complete clinical remission within seven days[1]. Clinical remission lasted 115 days on average[1]. The results were presented today at the Fifth International Congress on Familial Mediterranean Fevers and Systemic Autoinflammatory Diseases in Rome.
"The latest findings are a promising step forward for patients with rare autoinflammatory diseases," said Trevor Mundel, MD, Head of Global Development Functions at Novartis Pharma AG. "We are optimistic that ACZ885 could become an innovative treatment option for patients affected by inflammatory diseases involving IL-1ß. ACZ885 reflects our commitment to developing innovative treatments that address unmet medical needs, in patients with serious but rare conditions."
ACZ885 is also being investigated in more common inflammatory diseases such as rheumatoid arthritis (RA), which affects up to 1% of the world’s population[4]. A study in RA currently under way uses an innovative tailored approach with biomarkers to predict response to treatment. If successful, this will give suitable patients a personalized approach to treating their disease.
Unlike other agents, ACZ885 blocks solely interleukin 1ß (IL-1ß), one form of interleukin-1 protein that causes the body to ‘attack’ itself in autoinflammatory diseases such as CAPS. Patients affected by CAPS have symptoms such as fever, fatigue, skin rash, painful joints and muscles, and severe headache. They can also suffer from more severe complications like hearing loss and amyloidosis, a group of diseases in which some organs accumulate high deposits of proteins causing kidney failure and leading to dialysis or transplantation[3].
The study results presented in Rome involved 20 patients with CAPS aged between six and 50 years, who received an injection of ACZ885 every two months dosed at 150 mg for adults or two mg per kilo body-weight for children[1,2]. ACZ885 was well-tolerated in the study, with only mild skin reactions at the injection site. The most common adverse events were upper respiratory tract infections[2].
"Traditional drugs for autoinflammatory diseases, which work by suppressing the immune system as a whole, are not always effective, while newer therapies control the disease better but are short-acting," said Professor Philip Hawkins of the National Amyloidosis Centre at the Royal Free and University College Medical School, London. "The data for ACZ885 are exciting for the medical community as symptoms disappeared within a few days of treatment and the response was sustained, so patients may only need to be treated every second month."
The potential of ACZ885 is reflected in its broad development program. In addition to the Phase III study program in CAPS and the Phase II study in rheumatoid arthritis, a Phase II study is also ongoing in another condition called Systemic Onset Juvenile Idiopathic Arthritis (SJIA).
Orphan drug status has already been granted to ACZ885 in the European Union and US for treating CAPS, and in the EU for SJIA. Orphan drugs are those designed to treat serious or life-threatening diseases affecting less than 200,000 people (in the US)5 or less than five out of 10,000 people (in the EU)[6].
About Novartis
Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group’s continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.
References
[1.] Lachmann H.J. et al. Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-beta monoclonal antibody (ACZ885): results from a subcutaneous administration study, oral presentation at FMFSAID, April 8 2008, Rome, Italy.
[2.] Kuemmerle-Deschner J.B. et al, Long lasting response to ACZ885 in patients with Muckle-Wells Syndrome, oral presentation at FMFSAID, April 8 2008, Rome, Italy.
[3.] http://www.capscommunity.com/index.html, Last access March 17, http://www.orpha.net/consor/cgi-bin/index.php, Last access March 17
[4.] Data Monitor Report, 2007.
[5.] http://www.fda.gov/orphan, Last access March 17, 2008
[6.] http://ec.europa.eu/health/ph_threats/non_com/rare_6_en.htm, Last access March 17, 2008
SOURCE: NOVARTIS
Post Views: 106
